The PDCD10 (Programmed Cell Death 10) protein, also known as Cerebral Cavernous Malformation 3 (CCM3), is encoded by the *PDCD10* gene and plays a critical role in vascular development and maintaining blood vessel integrity. Initially identified for its association with apoptosis, PDCD10 is now recognized as a key component of the CCM signaling complex, interacting with CCM1 (KRIT1) and CCM2 to regulate endothelial cell junctions, cytoskeletal organization, and cell-matrix adhesion. Mutations in *PDCD10* are linked to cerebral cavernous malformations (CCMs), a vascular disorder characterized by fragile, leaky blood vessels in the brain, leading to seizures, strokes, or neurological deficits. PDCD10 antibodies are essential tools for studying these mechanisms, enabling detection of protein expression, localization, and interactions in cell and tissue samples. Researchers use these antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate PDCD10's role in vascular stability, angiogenesis, and disease pathology. Additionally, they aid in identifying pathogenic mutations and evaluating therapeutic strategies targeting CCM pathways. Commercial PDCD10 antibodies are typically validated for specificity and sensitivity, though variations in isoforms and post-translational modifications require careful experimental design.